Sorrento Therapeutics to Participate in Key Opinion Leader Panel Discussion on “New Horizons for the Treatment of Non-small Cell Lung Cancer”

Rhea-AI Summary

Sorrento Therapeutics (Nasdaq: SRNE) announces a KOL Panel Discussion on October 12, 2022, at 10:00 am ET, focusing on the unmet needs in non-small cell lung cancer. Dr. Mike A. Royal, the Chief Medical Officer, will discuss the potential of abivertinib, a novel EGFR/BTK inhibitor. The panel will include experts like Dr. Yi-long Wu and Dr. Brian S. Henick. This event underscores Sorrento's commitment to advancing cancer therapies and other innovative treatments. The discussion will be archived for future access on Sorrento's website.

Panel to Discuss Unmet Need in Non-small Cell Lung Cancer and the Potential for Abivertinib, a Novel Third Generation epidermal growth factor receptor / Bruton’s tyrosine kinase (EGFR/BTK) Inhibitor

SAN DIEGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that Dr. Mike A. Royal, Chief Medical Officer, will participate in an upcoming Key Opinion Leader (KOL) Panel Discussion that will focus on the great unmet need in non-small cell lung cancer and the potential of abivertinib, a novel, third-generation, EGFR/BTK inhibitor. Details are as follows:

Title:	New Horizons for the Treatment of Non-small Cell Lung Cancer
Format:	Panel Discussion
Moderator:	Raghuram Selvaraju, Ph.D., Managing Director of Equity Research at HC Wainwright
Panel Speaker:	Yi-long Wu, M.D., Ph.D., Professor at Guangdong Provincial People's Hospital, Guangzhou, China
Panel Speaker:	Brian S. Henick, M.D., Medical Oncologist at Columbia University Irving Medical Center
Company Speaker:	Mike A. Royal, M.D., Chief Medical Officer of Sorrento
Date/Time:	October 12, 2022 from 10:00 am – 11:30 am (Eastern Time)

The KOL Panel Discussion will be archived and can be accessed on the Investor Relations section of Sorrento’s website under Events, where you can also learn more about the panel participants’ backgrounds and biographies. (Events Calendar - Sorrento Therapeutics).

About Sorrento Therapeutics, Inc.

Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as next-generation tyrosine kinase inhibitors (“TKIs”), fully human antibodies (“G-MAB™ library”), immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates (“ADCs”), and oncolytic virus (“Seprehvec™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including STI-1558, Abivertinib, COVISHIELD™ and COVIDROPS™; and diagnostic test solutions, including COVIMARK™.

Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido^® (lidocaine topical system) 1.8% for the treatment of postherpetic neuralgia (PHN). RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients. Positive final results from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXA™, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. ZTlido^® was approved by the FDA on February 28, 2018.

For more information visit www.sorrentotherapeutics.com

Forward Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the expectations for Sorrento's and its subsidiaries' technologies and product candidates. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's and its subsidiaries', affiliates’ and partners’ technologies and prospects and collaborations with partners; risks related to seeking regulatory approvals and conducting clinical trials; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist Sorrento in the execution of its product candidates’ strategies; risks related to the global impact of COVID-19; and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2021, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Media and Investor Relations
Contact: Brian Cooley
Email: mediarelations@sorrentotherapeutics.com

Sorrento^® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

G-MAB™, DAR-T™, Seprehvec™, SOFUSA™, COVISHIELD™, COVIDROPS™, COVI-MSC™, COVIMARK™ and Fujovee™ are trademarks of Sorrento Therapeutics, Inc.

SEMDEXA™ (SP-102) is a trademark of Semnur Pharmaceuticals, Inc. A proprietary name review by the FDA is planned.

ZTlido^® is a registered trademark owned by Scilex Pharmaceuticals Inc.

All other trademarks are the property of their respective owners.

©2022 Sorrento Therapeutics, Inc. All Rights Reserved.

FAQ

What is the purpose of the KOL Panel Discussion featuring Sorrento Therapeutics on October 12, 2022?

The KOL Panel Discussion will address the unmet need in non-small cell lung cancer and explore the potential of abivertinib, a novel EGFR/BTK inhibitor.

Who will participate in the Sorrento Therapeutics KOL Panel Discussion on October 12, 2022?

Dr. Mike A. Royal will represent Sorrento, alongside experts like Dr. Yi-long Wu and Dr. Brian S. Henick.

How can I access the Sorrento Therapeutics KOL Panel Discussion after the event?

The discussion will be archived and available on the Investor Relations section of Sorrento's website.

What time is the Sorrento Therapeutics KOL Panel Discussion scheduled for?

The discussion is scheduled for October 12, 2022, from 10:00 am to 11:30 am Eastern Time.

What is abivertinib and its relevance to Sorrento Therapeutics?

Abivertinib is a novel third-generation EGFR/BTK inhibitor being discussed for its potential in treating non-small cell lung cancer.